Clicking on banner ads enables JWR to constantly improve
Jewish World Review May 24, 2002 / 13 Sivan, 5762

Doug Bandow

Doug Bandow
JWR's Pundits
World Editorial
Cartoon Showcase

Mallard Fillmore

Michael Barone
Mona Charen
Linda Chavez
Ann Coulter
Greg Crosby
Larry Elder
Don Feder
Suzanne Fields
Paul Greenberg
Bob Greene
Betsy Hart
Nat Hentoff
David Horowitz
Marianne Jennings
Michael Kelly
Mort Kondracke
Ch. Krauthammer
Lawrence Kudlow
Dr. Laura
John Leo
David Limbaugh
Michelle Malkin
Chris Matthews
Michael Medved
MUGGER
Kathleen Parker
Wes Pruden
Sam Schulman
Amity Shlaes
Tony Snow
Thomas Sowell
Cal Thomas
Jonathan S. Tobin
Ben Wattenberg
George Will
Bruce Williams
Walter Williams
Mort Zuckerman

Consumer Reports

Threatening pharmaceutical innovation

http://www.NewsAndOpinion.com | America's economic prosperity is built upon productivity and innovation, yet the entrepreneurial process is under constant attack. Sometimes the assault is direct, as in the case of Microsoft. More often it is indirect, as in the case of the pharmaceutical industry.

Federal and state officials are seeking to control prices, limit sales, destroy industry marketing networks and undercut patent rights. These efforts could hobble an industry that today dominates the globe while providing manifold health benefits through new drug discoveries.

Pharmaceutical innovation depends on the patents, which allow companies to profit from their research. Otherwise the industry would not spend more than $30 billion a year to develop new products.

Indeed, industry R&D averages 20 percent of sales, five times the American average. The industry figures that it spends an average of nearly $900 million per drug.

Even such a significant investment doesn't guarantee results. Of every 5,000 to 10,000 substances reviewed, only one ultimately makes it onto the market. Just a third of them actually make money. These few must pay for everything -- research, administration and costly "dry holes."

No wonder then, that doctors support pharmaceutical patents. In a recent survey, 98 percent of physicians said that continued drug development is important or somewhat important for patient care.

Unfortunately, however, drugs do not just appear. Three-fourths of doctors opined that patent rights were very important as an incentive for drug production; 23 percent said that they were somewhat important.

Nevertheless, patents do not run forever, creating room for a vibrant generic industry. In 1984, Congress approved legislation relieving the regulatory burden on generics, which have gone from one-fifth to half of the market. This has tempered drug prices and restrained pharmaceutical costs. Yet patent battles have become common. The FDA's unnecessarily lengthy approval process undercuts the value of patents, causing Congress to allow for their extension if, for instance, a manufacturer adds a new chemical to the drug or develops a new use for the drug.

At the same time, a variety of interests often strongly resist patent extensions. The Federal Trade Commission just settled a case with Biovail Corp. involving its attempt to maintain the patent on the blood pressure medicine Tiazac. Controversy also has dogged AstraZeneca's effort to extend the patent life for Prilosec, which combats heartburn, Myers Squibb's Glucopohage, which treats diabetes, and Schering-Plough's Claritin, which mitigates allergies.

Whatever the specifics of individual cases, there is nothing wrong in principle with research firms attempting to extend their patents within the law. After all, the companies were created to make money; if they didn't, they wouldn't invest in R&D. The very purpose of patents is to provide a temporary monopoly to allow companies to enjoy the fruit of their labor.

Some legislators would change the law -- Sens. Charles Schumer (D-N.Y.) and John McCain (R-Ariz.) want to close the "loopholes" that allow patent extensions. Pharmacist Lee Vermeulen of the University of Wisconsin suggests that the Food and Drug Administration block medicines which don't offer a significant advance over existing products: "We can't afford this kind of nonsense from the industry."

Health insurers are working to move patented products into the over-the-counter market. Some industry critics hope to discourage use of newer, patented drugs developed to replace older, off-patent medicines by banning consumer advertising, for instance. Medical reporter M. Alexander Otto, writing in the Washington Post, even complained that Schering-Plough had priced its antihistamine Clarinex lower than the drug it superseded, Claritin.

Any attempt to limit patent protection creates risks, however. Pharmaceuticals are well worth the cost: not only do they extend and improve the quality of life, but they reduce other medical expenditures, particularly for hospitalization and surgery.

No surprise, then, more than two-thirds of doctors worry that weakening patent protection will reduce research on rarer conditions and actually raise consumer prices, by forcing recovery of costs in a shorter period of time. A majority also fear that the result will be fewer generics, since the latter ultimately derive from brand drug development.

Advertising informs consumers, alerting some people to conditions and cures of which they were unaware; even doctors have trouble keeping up with the flood of medical advances. Moreover, physicians remain the gatekeeper, reviewing the appropriateness of a particular treatment.

Even "me-too" drugs often offer important advantages for some people. Doctors prescribing and patients taking newer products, not special interests lobbying politicians, should determine the relative advantages of, say, Schering-Plough's Clarinex over Claritin, or AstraZeneca's Nexium over Prilosec. They should decide whether any improvements are worth the added costs.

Generics have become a critical component of the drug market. But without patents, there would be no brand name medicines to copy. In attempting to lower health-care costs, we must not kill the pharmaceutical Golden Goose.



JWR contributor Doug Bandow is a senior fellow at the Cato Institute. Comment by clicking here.

Up


05/14/02: The war crimes fantasy
05/07/02: Paying a high price for befriending Saudi princes
04/30/02: The price of postal monopoly
04/23/02: The war on charity
04/16/02: The forgotten human right
03/27/02: Cuba's struggle to be free
03/20/02: How to defeat Cuban communism
03/12/02: Junk science, redux
03/06/02: Axis of hubris
02/27/02: Washington-style campaign reform: incumbent protection
02/20/02: The grand Enron morality play
02/12/02: Rebuilding what?
02/05/02: Succumbing to the terrorist temptation
01/29/02: Democrats for what?
01/22/02: The Iraqi question
01/14/02: Profiling frequent flyers
01/08/02: Trade, not aid
01/02/02: Treason by any other name
12/26/01: Preserving freedom in an unfree world
12/17/01: Dealing with terrorism's aftermath
12/10/01: Emerging friendships?
12/04/01: Uncle Sam: Insurer of last resort
11/28/01: Expanding the circle of trade
11/20/01: Free to be stupid
11/13/01: The meaning of compassion
11/07/01: Patriotic scoundrels
10/30/01: The coming postal raid
10/16/01: First, do no harm
10/12/01: Good news from a suffering land
10/04/01: Defending whom?
09/25/01: The wrong solution to the wrong problem
09/21/01: The price of terrorism
08/28/01: Uncle Sam's retirement scam
08/21/01: Canberra's quaint naivete
08/14/01: Uncle Sam's false fuel economy
08/08/01: The Clinton administration in drag
07/31/01: The high cost of government
07/24/01: Kill the campaign reform illusion
07/17/01: Do as I say, not as I do
07/11/01: Lawyers at play
07/05/01: Western blundering, Macedonian disaster
06/26/01: How best to honor Bill Clinton?
06/19/01: A maturing Europe?
06/15/01: Tell Beijing to mind its own business
06/06/01: Ukraine's boiling cauldron
05/31/01: Protecting privacy from Uncle Sam
05/22/01: America's Balkan quagmire
05/09/01: The Taiwanese flash point
05/01/01: Globalization serves the world's poor
04/24/01: Who's cheating whom?
04/10/01: The NCAA scam
04/03/01: Balkan stupidities
03/27/01: McCain doesn't want a 'risk for our country'
03/20/01: Dubious Korean alliances
03/06/01: Coercive patriotism
02/27/01: Bombing without end
02/20/01: A dose of misplaced outrage
02/13/01: Psst: Tax cuts for taxpayers. Pass-it-on
02/06/01: Bridging the unbridgeable gap
01/23/01: Left-wing demagoguery
01/16/01: The drug war problem
01/10/01: Politics and trade
01/03/01: Hope for liberty?
12/27/00: The debris of war
12/19/00: What's the rule of law for?
12/15/00: Ending silicone breast implant saga
12/05/00: Election may yield victor, but there are no winners
11/21/00: A Bush presidential mandate?
11/07/00: Exprienced Gore? Yeah, right
11/01/00: Interventionist follies
10/17/00: America's brightening prospects in Ukraine
10/11/00: GOP budget scandals
10/03/00: How a pharmaceutical 'crisis' was created
09/27/00: Clinton's empathy has helped nobody
09/13/00: AlGore's risky budget policies
09/05/00: Military readiness and Korean commitments
08/29/00: Let sleeping hypocrites lie
08/21/00: Targeting a journalistic pariah
08/15/00: European garrison for Kosovo?
08/08/00: Journalistic cleansing at the Boston Globe
08/04/00: Junk science on trial
06/22/00: Eternal vigilance is the price of liberty
06/15/00: The end of U.N. peacekeeping
06/07/00: The Clinton regulatory miasma
06/01/00: Administration stupidity, congressional cowardice
05/25/00: The silence of the international community
05/18/00: Protecting the next generation

05/11/00: Freer trade with China will advance human rights

05/04/00: How not to save the Constitution

04/28/00: American tripwire in Korea long ago disappeared: Why are we still involved?

04/18/00: Clinton administration believes the IRS is too gentle, wants more auditors

© 2002, Copley News Service